company background image
300363 logo

Porton Pharma Solutions SZSE:300363 Stock Report

Last Price

CN¥11.97

Market Cap

CN¥6.3b

7D

2.3%

1Y

-53.0%

Updated

24 Sep, 2024

Data

Company Financials +

Porton Pharma Solutions Ltd.

SZSE:300363 Stock Report

Market Cap: CN¥6.3b

300363 Stock Overview

Engages in the manufacture and sale of small molecule active pharmaceutical ingredients, dosage forms, and biologics to the pharmaceutical companies in China, the United States, and Europe.

300363 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends3/6

Porton Pharma Solutions Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Porton Pharma Solutions
Historical stock prices
Current Share PriceCN¥11.97
52 Week HighCN¥32.66
52 Week LowCN¥10.91
Beta0.10
11 Month Change4.63%
3 Month Change-5.52%
1 Year Change-52.99%
33 Year Change-87.48%
5 Year Change-12.95%
Change since IPO24.17%

Recent News & Updates

Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Jun 26
Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Analysts Just Shaved Their Porton Pharma Solutions Ltd. (SZSE:300363) Forecasts Dramatically

May 02
Analysts Just Shaved Their Porton Pharma Solutions Ltd. (SZSE:300363) Forecasts Dramatically

Recent updates

Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Jun 26
Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Analysts Just Shaved Their Porton Pharma Solutions Ltd. (SZSE:300363) Forecasts Dramatically

May 02
Analysts Just Shaved Their Porton Pharma Solutions Ltd. (SZSE:300363) Forecasts Dramatically

Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?

Mar 26
Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?

Porton Pharma Solutions Ltd.'s (SZSE:300363) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Mar 04
Porton Pharma Solutions Ltd.'s (SZSE:300363) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Shareholder Returns

300363CN PharmaceuticalsCN Market
7D2.3%-1.2%1.1%
1Y-53.0%-18.9%-20.4%

Return vs Industry: 300363 underperformed the CN Pharmaceuticals industry which returned -18.9% over the past year.

Return vs Market: 300363 underperformed the CN Market which returned -20.4% over the past year.

Price Volatility

Is 300363's price volatile compared to industry and market?
300363 volatility
300363 Average Weekly Movement5.5%
Pharmaceuticals Industry Average Movement5.1%
Market Average Movement5.4%
10% most volatile stocks in CN Market8.5%
10% least volatile stocks in CN Market3.6%

Stable Share Price: 300363 has not had significant price volatility in the past 3 months.

Volatility Over Time: 300363's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20054,300Nianfeng Juwww.porton.cn

Porton Pharma Solutions Ltd. engages in the manufacture and sale of small molecule active pharmaceutical ingredients, dosage forms, and biologics to the pharmaceutical companies in China, the United States, and Europe. The company was formerly known as Porton Fine Chemicals Ltd. and changed its name to Porton Pharma Solutions Ltd.

Porton Pharma Solutions Ltd. Fundamentals Summary

How do Porton Pharma Solutions's earnings and revenue compare to its market cap?
300363 fundamental statistics
Market capCN¥6.26b
Earnings (TTM)-CN¥313.55m
Revenue (TTM)CN¥2.68b

2.4x

P/S Ratio

-20.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
300363 income statement (TTM)
RevenueCN¥2.68b
Cost of RevenueCN¥2.09b
Gross ProfitCN¥591.45m
Other ExpensesCN¥905.00m
Earnings-CN¥313.55m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.57
Gross Margin22.06%
Net Profit Margin-11.70%
Debt/Equity Ratio23.4%

How did 300363 perform over the long term?

See historical performance and comparison

Dividends

4.1%

Current Dividend Yield

-85%

Payout Ratio